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Summary Background. Despite decades of use, the magnitude of efficacy of narrowband
ultraviolet B (NB-UVB) phototherapy for atopic dermatitis (AD) beyond industry-
sponsored trials remains unclear.
Aim. To evaluate the clinical efficacy of NB-UVB in AD under real-world condi-
tions.
Methods. We conducted a historical inception cohort study using automated
recording of dispensed drugs to provide an objective treatment outcome in a large
population catchment of 420 000 people over 15 years. We analysed clinical treat-
ment outcomes, recorded multicentre and prospectively over 15 years, of a large AD
treatment cohort (n = 844), along with the drugs dispensed to this cohort.
Results. The majority (70%) of patients with AD received significantly fewer topical
corticosteroids (TCS) during the 12-month window after finishing NB-UVB compared
with the 12-month window before starting the treatment (median reduction from
37.5 to 19.7 g/month). The number of patients dispensed with oral corticosteroids
and antihistamines also dropped significantly (from 20% to 10% and from 69% to
31%, respectively), while all AD-unrelated drugs dispensed remained unchanged.
Clinically, NB-UVB treatment achieved a ‘clear’ or ‘almost clear’ status in 48.7% of
patients, while 20.4% achieved ‘moderate clearance’. Treatment outcomes scores
were validated by a strong correlation with reduction in AD-specific drug treatment.
Conclusion. Our data confirm the significant efficacy of NB-UVB for AD under con-
ditions of routine care.
Introduction
Narrowband ultraviolet B (NB-UVB) has been in use
for atopic dermatitis (AD) for decades, and its efficacy
has been confirmed in randomized controlled trials.1,2
However, data on efficacy beyond formal studies are
limited to small studies or case series,1–4 some focused
only on children,5–9 and a lack of information on
efficacy under real-world conditions is well recog-
nized.10 The assessment of efficacy beyond controlled
interventional studies is limited by a number of issues,
including (i) lack of prospective data collection, (ii)
patient selection bias and (iii) recording bias due to
incomplete data return. The population in Tayside in
Scotland receives near-complete provision of health-
care organized by a single provider (the National
Health Service) that offers resources addressing these
limitations, including automated capture of all pre-
scription drugs, prospectively collected NB-UVB treat-
ment outcomes, electronic recording of specialist-
validated diagnoses and review status for all patients
referred for treatment from primary care in a
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population catchment of 420 000. Using these
resources, we previously reported on the clinical char-
acteristics of patients with AD not controlled in pri-
mary care, along with the amounts of topical
corticosteroids (TCS) and emollients dispensed to these
patients.11
Randomized controlled trials commonly report out-
comes for AD treatments, using instruments such as
the Eczema Area and Severity Index (EASI) and
SCORing Atopic Dermatitis (SCORAD), in a blinded
manner. By contrast, in routine clinical care, out-
come monitoring is aimed at establishing if a per-
ceived benefit would justify potential future repeat
treatment for a given patient. Therefore, clinical out-
comes are openly recorded on a categorical scale
with respect to change from baseline. Notably, despite
the lack of blinding, we previously observed that the
clinically assigned outcomes recorded for NB-UVB
correlate with prospectively and assessor-blinded
effects on consumption of TCS in psoriasis.12 We
therefore sought to explore whether clinical outcome
scoring could also provide a valid measure of efficacy
in AD.
A general limitation in real-world AD studies is that
the severity of disease at baseline is not strictly quanti-
fied in routine clinical care. Therefore, patient popula-
tions are more heterogeneous than those studied in
interventional trials. In this regard, we previously
detailed the clinical severity profile of all patients with
AD referred to dermatology departments from primary
care in Tayside/North-East Fife.11 We report the effi-
cacy of NB-UVB in AD under conditions of routine
clinical care.
Methods
Owing to space constraints, the ethics and STROBE
statements, along with a detailed Methods section
have been placed into Data S1 except for the following
brief summary on study design.
Overall study design
This was an inception cohort study combining
prospective and retrospective elements as follows. At
the time of administration, NB-UVB formed part of
routine medical care. This study included all consecu-
tive treatment courses meeting the inclusion criteria
(failure of topical treatment and suitability for pho-
totherapy, see Data S1 for Methods). The primary out-
come measures included the quantities of TCS
dispensed in primary care for the 12 months before
and 12 months after NB-UVB treatment course. These
data were collected prospectively, either blinded (dis-
pensed drugs) or open (NB-UVB therapy clinical out-
come score). Data on dispensed drugs were gathered
from Health Informatic Centre Tayside, while clinical
outcomes of NB-UVB therapy, rated by both pho-
totherapy nurses and patients combined, were col-
lected using datasets derived from the Photosys
database at four independent treatment sites. Data
analysis and statistical testing were performed retro-
spectively. Patient selection, assembly of cohort, data
refinement and quality checks have been described in
detail prevously.11 Definition of observational window,
cohort refinement and validation are detailed in Data
S1. The overall design was a nonplacebo-controlled
before-versus-after treatment analysis as detailed in
Results below.
Results
A large multicentre real-world atopic dermatitis
treatment cohort
Table 1 summarizes the baseline characteristics of the
patient cohort prior to receiving NB-UVB. Patients
received near-universal regular TCS, and exhibited a
comorbidity profile in keeping with active AD
(Table 1). Approximately one-fifth of patients had
received oral systemic corticosteroids prior to NB-UVB,
while the cohort was largely na€ıve to other systemic
immunosuppressive treatments. Body surface area
(BSA) and EASI data had not been collected as part of
routine care. Nonetheless, the availability of quantita-
tive monthly data on TCS dispensed makes it likely
that mean BSA involvement exceeded 10% at baseline
across the cohort, as detailed previously.11 This infer-
ence was further supported by measurement of EASI
in an explorative patient group at baseline, which
yielded a mean  SD score of 22  12 (n = 6). In
addition, the presence of continued active AD in this
patient cohort is further supported by the fact that sig-
nificant time elapsed between primary care referral
and (i) initial dermatology review (range 2–10 weeks),
(ii) initiation of phototherapy (2–8 weeks) and (iii)
completion of the first 10 courses of treatment (range
1–89 treatments per course). The patients comprising
this cohort did not default appointments or drop out
early, all of which makes spontaneous substantial
improvement of their condition unlikely. Taken
together, despite the lack of EASI/SCORAD data, the
cohort presented here probably represents a moderate
to severe AD phenotype.
ª 2021 The Authors. Clinical and Experimental Dermatology published by
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Significant reduction of topical corticosteroids
dispensed after narrowband ultraviolet B treatment
The data for dispensed TCS are electronically captured
for all patients (see Methods). Observers are blinded to
this quantity. Hence, the TCS dispensed before vs. after
NB-UVB treatment provides a prospectively collected,
objective clinical endpoint. To minimize seasonal fluctu-
ations impacting on the dispensed TCS data, we anal-
ysed the mean dispensed TCS or the 12 months before
and 12 months after NB-UVB treatment. The mean
number of NB-UVB treatments per course received was
27 (interquartile range 17). Data were analysed for the
entire cohort, as well as for three age-range subgroups
(< 16, 16–25, > 25 years), respectively,11 with the cut-
off between these groups chosen as the best fit to the
age distribution observed within this cohort.
As shown in Table 2, we observed an overall reduc-
tion of median TCS dispensed from 37.5 to
19.7 g/month following NB-UVB (P < 0.001), mirror-
ing a marked increase in the number of patients not
requiring any TCS at all among the adult cohorts
(Fig. 1a). We also noted a slight decrease in the dis-
pensed emollients, reaching borderline significance in
male patients (Fig. S1). Approximately 70% of patients
exhibited a decrease in TCS dispensed (Fig. 1b).
Despite the overall mean reduction in dispensed TCS,
there was individual patient variability, with some
patients showing only a slight decrease and some
showing an increase in the amount of TCS received.
This variability might partly be explained by greater
use of milder TCS products, although we did not anal-
yse dispensed TCS by potency. When analysed by sex,
changes were more pronounced in female patients
(Fig. 1c). As expected, the reduction in dispensed TCS
was even greater within the first 3 months immedi-
ately after NB-UVB (Fig. S2). Furthermore, the number
of patients who were started on systemic immunosup-
pressive treatment during the 12 months after NB-
UVB treatment remained small at 1.1% (n = 10), par-
ticularly in the context of there being six patients who
had received immunosuppressive treatment prior to
phototherapy, suggesting that the observed 12-month
data probably represent a continued prolonged effect
of the phototherapy treatment.
Changes in drug treatment after narrowband
ultraviolet B are specific to atopic dermatitis-targeted
treatments
We also observed a significant reduction in the num-
ber of patients dispensed antihistamines or oral sys-
temic corticosteroids after NB-UVB (Fig. S3). By
Table 1 Baseline clinical characteristics of the patients with ato-
pic dermatitis treated with narrowband ultraviolet B.a
Clinical characteristics n (%)
Age, years; mean  SD 30.8  16.5
Male, % 46.9
Baseline UVB, MEDb; mean  SD 0.17  0.086
Pre NB-UVB treatment status, n (%)
Dispensed TCS 762 (94.3)c
Oral systemic corticosteroid treatmentd 167 (19.8)
Other systemic treatments for ADe 6 (0.7)
Atopic comorbidities, n (%)
Asthmaf 243 (28.8)
Elevated IgE 249 (82.5)
Allergic rhinitis 93 (11)
AD, atopic dermatitis; MED, minimal erythema dose; NB, nar-
rowband; TCS, topical corticosteroid; UVB, ultraviolet B. aThe
treatment cohort comprised all patients with AD referred for a
first-ever course of NB-UVB for AD not controlled by topical
treatment during the period 1 January 19861 September
2017. A comprehensive co-morbidity spectrum of the patient
cohort has been reported previously.11 For details, see Methods.
bMED to NB-UVB at 24-h reading. cValue shown represents the
percentage observed (90.3%) after correction for missing data
(Information Services Division Scotland reported overall com-
pleteness of data capture of 95.8%  1.0% for the index years
2010–2016). dAt least one course of oral systemic corticosteroids
in the 12 months prior to NB-UVB. eMethotrexate, ciclosporin,
azathioprine. fDefined by required regular dispensing of asthma-
specific British National Formulary-coded preparations prior to
baseline.11
Table 2 Monthly dispensed topical corticosteroid to patients with














70.0 50–89 54.6 55.3 39–71 32.5
16–25
(n = 314)
43.5 39–47 34.8 32.8 27–38 16.6*
> 25
(n = 373)
54.0 47–60 35.8 46.0 36–55 21.6*
TCS, topical corticosteroid. aData shown include patients with
atopic dermatitis not receiving TCS (approximately 5%). The cor-
responding data, excluding any patients not receiving any TCS
treatment are shown in Table S7. *P < 0.001 for before vs. after
narrowband ultraviolet B (Wilcoxon matched-pairs signed-rank
test).
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contrast, there were no changes in any of a large
number of treatments unrelated to AD (Table S1).
Significantly improved clinical outcome in almost half
of patients did not differ significantly across four
independent treatment sites
We next analysed the recorded clinical outcomes of
NB-UVB based on nurse assessor combined with
patient’s opinion, using a categorical scale (Fig. S4a).
As clinical outcomes are assigned without blinding,
we initially performed a systematic analysis of bias.
Recorded outcomes did not significantly differ between
four independent treatment sites staffed by different
raters (Fig. S4b). They also remained remarkably
stable across > 2 decades (Fig. S4c), indicating resili-
ence to ‘scoring drift’ over time. Overall, a clinical out-
come of ‘significant improvement’, which included the
outcomes of ‘clear’ or ‘almost clear’, was assigned to
48.7% of patients with AD, whereas ‘moderate clear-
ance’ was assigned to 20.4% of patients with AD (in-
cluding patients lacking recorded outcome, who were
conservatively scored as ‘not improved’).
Clinical outcome scores are independently validated by
the impact of narrowband ultraviolet B on dispensed
topical corticosteroids
We next asked whether the clinically recorded out-
comes correlate with the measured reduction in dis-
pensed TCS. As shown in Fig. 2a, the reduction in
dispensed TCS after finishing treatment was greatest in
patients recorded as significantly improved and smallest
in those without clinically recorded improvement, both
in terms of the actual quantity of dispensed TCS
(Fig. 2a) and the number of prescriptions filled per
patient (Table 3). Importantly, these results did not
change after exclusion of patients with minimal UVB
exposure (Table S2). Equally, the results did not change
after exclusion of patients with concurrent potentially
confounding diagnoses (psoriasis, discoid eczema, urti-
caria; Fig. S5). Furthermore, the number of patients
exhibiting a substantial reduction in dispensed TCS (de-
fined as ≥ 25%) was also significantly associated with
clinical outcome groups (Fig. 2b). Taken together, clini-
cal outcome, assessed at the conclusion of treatment,
strongly correlated with reduction of dispensed TCS
during the subsequent 12 months.
Figure 1 (a–c) Monthly topical corticosteroids (TCS) dispensed to patients with atopic dermatitis (AD) 12 months before and 12 months
after a course of narrowband ultraviolet B (NB-UVB) treatment. (a) Percentage of patients with AD receiving no TCS 12 months before
(grey) and 12 months after (white) NB-UVB, broken down by sex (Pearson v2 test). (b) Distribution of change in quantity (g) of dis-
pensed TCS (g) in the cohort of patients with AD during the 12 months before and 12 months after NB-UVB. (c) Monthly quantity (g)
of dispensed TCS, stratified by all patients and by sex during the 12 months before (grey) and 12 months after (white) NB-UVB.
Box plots represent median (line), 25th and 75th percentile (boxed), minimum and maximum, respectively (Wilcoxon matched-pairs
signed-rank test). ***P < 0.001.
ª 2021 The Authors. Clinical and Experimental Dermatology published by
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Patients with good clinical outcome after narrowband
ultraviolet B exhibit greater reduction in
antihistamines and oral systemic corticosteroids
dispensed
We next analysed all other treatments before vs. after
NB-UVB in the three clinical outcome subgroups. As
shown in Fig. 3, patients with substantial clinical
improvement also showed a significantly greater
reduction in treatment with oral systemic corticos-
teroids and in antihistamines, but not in any non-AD-
related drug treatment. These data further support the
validity of the clinical recorded outcomes.
Discussion
NB-UVB is widely used as a treatment for moderate to
severe AD. However, the lack of objective clinical
outcome measures available in routine clinical care
has prevented reliable assessment of efficacy under
real-world conditions. In this study, we analysed the
efficacy of NB-UVB using automated prescription cap-
ture as an objective outcome measure in a large real-
world cohort. Collected at the point of drug dispensing,
these data allow quantification of the actual AD medi-
cations issued to patients. Overall, NB-UVB caused a
significant reduction in median dispensed TCS, which
was sustained for at least a year after treatment and is
of clinical relevance.13 There were also reductions in
dispensed antihistamines (reflecting the antipruritic
activity of NB-UVB)14 and oral systemic corticos-
teroids, but none in AD-unrelated treatments.
In addition to objective recording of dispensed
drugs, we analysed in detail the validity and overall
result of clinical outcome recording. Despite the lack
of blinding, the assignment of clinical outcomes did
not differ significantly across different raters in four
independent treatment sites or across different years.
This may be due to the fact that scores are not
recorded to confirm efficacy but rather as a manage-
ment guide to inform decisions on future repeat treat-
ment. The validity of the assigned clinical scores is
further supported by the significant overlap between
these scores and the reduction in dispensed TCS, anti-
histamines and oral systemic corticosteroids. Future
studies are needed to assess the effect of NB-UVB on
quality of life (QoL).15
In terms of prediction of treatment outcome, none
of the potential predictors available at baseline, includ-
ing dispensed TCS or antihistamines, minimal ery-
thema UVB dose, age or sex was associated with
clinical outcome. Genetic association studies, e.g. using
the population-based recruitment strategies previously
used for psoriasis,16 might uncover predictive markers
allowing prospective identification of patients likely to
benefit from treatment.
There were some limitations to this study. It was a
noncomparative study. We used drugs dispensed to
patients or drugs received by patients as a proxy for
drug use in the interpretation. Data on the strength of
the TCS received by the patients were not available,
therefore, changes in TCS potency such as an
increased amount of milder TCS or a reduced amount
of more potent TCS dispensed to patients after NB-UVB
therapy were not captured. The results reported here
may not transfer to populations exhibiting a different
genetic background. Other limitations include the rela-
tively low number of patients in both the young and
older population segments, the lack of access to direct
quantitative data on pretreatment disease severity, and
Figure 2 (a,b) The amount of topical corticosteroids (TCS) dis-
pensed monthly, based on clinical improvement. (a) The amount
(g) of TCS per month dispensed to patients with atopic dermatitis
12 months before (grey) and 12 months after (white) narrow-
band ultraviolet B (NB-UVB), broken down by the three clinical
outcome groups. Box plots represent median (line), 25th and
75th percentile (boxed), 10th and 90th percentiles (Wilcoxon
matched-pairs signed-rank test). (b) Percentage of patients with
at least 25% reduction in TCS during the 12 months before and
the 12 months after NB-UVB, grouped by clinical improvement
(Kruskal–Wallis rank test). *P < 0.05, ***P < 0.001.
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other pertinent clinical features such as body mass
index or measures of QoL.17
Conclusion
NB-UVB leads to reported clearance and near-
clearance in roughly half of patients with moderate to
severe AD under real-world conditions, and 70% of
patients exhibit significantly reduced dispensed TCS.
Measurement of dispensed drugs may afford an impor-
tant clinical endpoint that will be useful to define the
impact of emerging systemic treatments.
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Table 3 The annual number of prescriptions filled per patient for atopic dermatitis-related drugs before and after narrowband ultravio-
let B treatment.a
Recorded response
TCSb, mean  SD (range)
Antihistamines, mean  SD
(range)
Systemic steroids, mean  SD
(range)
Before After Before After Before After




































NB, narrowband; TCS, topical corticosteroid; UVB ultraviolet B. aPrescriptions filled during either the interval 12 months prior to
(‘Before’) or subsequent to completing (‘After’) a course of NB-UVB (see Methods). Data comprise all treatment episodes where a definite
outcome was recorded. bTo exclude the potential artefact that the observed smaller reduction in dispensed TCS to patients classed clini-
cally as nonresponders might simply be due to the greater number of patients in this patient group who only had minimal exposure to
UV, we also analysed the data after exclusion of patients with < 10 UVB treatment sessions (Table S2), but this did not show any sub-
stantive difference. cTCS treatment data varying significantly between clinical outcome groups. *P = 0.001 (Kruskal–Wallis rank test).
Figure 3 Percentage of patients receiving atopic dermatitis (AD)-related drugs 12 months before (grey) and 12 months after (white)
narrowband ultraviolet B phototherapy treatment course based on clinical improvement: top row shows topical corticosteroids, antihis-
tamines and oral systemic corticosteroids; bottom row shows AD-unrelated drugs such as antihypertensives, lipid-regulating drugs and
antidepressants. A comprehensive list of all AD-unrelated drugs prescribed to patients is detailed in Table S1 (Pearson v2 test).
**P < 0.01, ***P < 0.001.
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What’s already known about this topic?
• NB-UVB has shown efficacy in AD in small clin-
ical trials.
What does this study add?
• In this study, 70% of patients with AD showed
a significant reduction in dispensed TCS during
the 12-month period after finishing NB-UVB,
compared with before starting NB-UVB.
• This reduction lasted for at least a year after
treatment.
• NB-UVB treatment achieved a ‘clear’ or ‘almost
clear’ status in 48.7% of patients.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
File S1. Contains the additional material described in
brief below.
Table S1. The number of prescriptions of atopic der-
matitis-unrelated drugs received by patients before and
after narrowband ultraviolet B.
Table S2. Atopic dermatitis-related prescriptions for
patients before and after at least 10 treatments per
course of narrowband ultraviolet B.
Table S3. The observational windows for atopic der-
matitis-related and atopic dermatitis-unrelated drug
prescriptions and quantity of drug dispensed, respec-
tively.
Table S4. Monthly topical corticosteroids dispensed
before vs. after exclusion of patients with concurrent
chronic inflammatory confounding diagnoses.
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Table S5. Monthly topical corticosteroids dispensed
before vs. after exclusion of patients with 2nd treat-
ment commenced within 12 months after first course
of narrowband ultraviolet B.
Table S6. Monthly topical corticosteroids dispensed
between patients with and without second treatment
commenced within 12 months after first course of
narrowband ultraviolet B, respectively.
Table S7. Monthly topical corticosteroids dispensed
limited to atopic dermatitis patients receiving topical
corticosteroids prescriptions before and after narrow-
band ultraviolet B, respectively.
Figure S1. Daily amount of emollient (in grams) dis-
pensed to patients during 12 months before narrow-
band ultraviolet B (grey) and 12 months after
narrowband ultraviolet B (white), respectively, broken
down by sex.
Figure S2. The monthly amount of topical corticos-
teroids (in grams) dispensed to patients with atopic
dermatitis patients during the first 3 months after nar-
rowband ultraviolet B (grey), as well as the entire 12-
month interval after narrowband ultraviolet B (white),
respectively, broken down by sex and age range.
Figure S3. The number of patients with atopic der-
matitis (%) who received topical corticosteroid,
antihistamine and systemic corticosteroid respectively,
12 months before (grey) and 12 months after (white)
narrowband ultraviolet B, respectively.
Figure S4. The overall clinical outcome of narrow-
band ultraviolet B treatment for atopic dermatitis
under real-world conditions in NHS Tayside.
Figure S5. Monthly topical corticosteroids (in grams)
dispensed to atopic dermatitis patients during
12 months before (grey) and 12 months after (white)
narrowband ultraviolet B, respectively, after exclusion
of patients with concurrent chronic inflammatory con-
founding diagnoses.
Figure S6. Ultraviolet B analysis for clinical vs. tech-
nical efficacy of narrowband ultraviolet B.
Figure S7. The distribution of patients (in %) with
their respective number of treatments per course of
narrowband ultraviolet B, broken down by the three
main clinical outcomes.
Figure S8. The distribution of clinical outcomes (in
%) between subgroups of patients with and without
second ultraviolet B treatment commenced within
12 months of post narrowband ultraviolet B period,
including only patients with minimal exposure (at
least 10 treatments per course) in the first exposure of
narrowband ultraviolet B in both subgroups.
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